NEW H1-RECEPTOR ANTAGONISTS - CLINICAL-PHARMACOLOGY

被引：19

作者：

SIMONS, FER ^{[1
]}

机构：

[1] UNIV MANITOBA,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA

来源：

CLINICAL AND EXPERIMENTAL ALLERGY | 1990年 / 20卷

关键词：

D O I：

10.1111/j.1365-2222.1990.tb02457.x

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

The non‐sedating, second‐generation H1‐receptor antagonists such as terfenadine, astemizole, loratadine and cetirizine differ considerably from each other in their pharmacokinetics and pharmacodynamics. They are generally well absorbed when administered orally. They have extremely variable serum elimination half‐life values. The maximum antihistaminic effect of these medications occurs several hours later than peak serum concentrations do. The duration of the antihistaminic effect is much longer than would be predicted from the serum elimination half‐life values. The relative incidence of anticholinergic and central nervous system adverse effects caused by these medications is similar to that produced by placebo. The introduction of the second‐generation H1‐receptor antagonists represents a major advance in symptomatic therapy of allergic disorders such as allergic rhinitis and urticaria. Copyright © 1990, Wiley Blackwell. All rights reserved

引用

页码：19 / 24

页数：6

共 36 条

[21] ATTENUATION OF CUTANEOUS REACTIVITY TO HISTAMINE BY CETIRIZINE AND DEXCHLORPHENIRAMINE [J].